Try our Advanced Search for more refined results

Kyle Bass Group Gets PTAB To Review 2 Celgene Patents

By Ryan Davis ( October 27, 2015, 8:38 PM EDT) -- The Patent Trial and Appeal Board on Tuesday agreed to review two more drug patents challenged by hedge fund manager Kyle Bass, finding that his organization has shown that two Celgene Corp. patents related to the cancer drugs Thalomid, Revlimid and Pomalyst are likely invalid....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections

PTAB Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Date Filed

Subscribers Only

Law Firms

Companies

Government Agencies

Patents

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!